Wall Street analysts expect Aldeyra Therapeutics, Inc (NASDAQ:ALDX) to report earnings of ($0.47) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Aldeyra Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.47) and the highest estimate coming in at ($0.46). Aldeyra Therapeutics posted earnings per share of ($0.32) in the same quarter last year, which would indicate a negative year over year growth rate of 46.9%. The company is expected to announce its next quarterly earnings report on Thursday, November 8th.
On average, analysts expect that Aldeyra Therapeutics will report full year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($1.83) to ($1.73). For the next financial year, analysts expect that the company will post earnings of ($1.65) per share, with EPS estimates ranging from ($1.73) to ($1.53). Zacks’ EPS calculations are an average based on a survey of research firms that follow Aldeyra Therapeutics.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.03).
ALDX has been the topic of a number of research reports. ValuEngine raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, September 20th. Janney Montgomery Scott initiated coverage on shares of Aldeyra Therapeutics in a research note on Thursday, September 13th. They issued a “buy” rating on the stock. Cantor Fitzgerald set a $23.00 target price on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, September 5th. Canaccord Genuity reissued a “buy” rating and issued a $27.00 target price on shares of Aldeyra Therapeutics in a research note on Friday, August 10th. Finally, Zacks Investment Research raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $24.92.
Hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in Aldeyra Therapeutics in the 2nd quarter valued at approximately $1,335,000. Dimensional Fund Advisors LP increased its holdings in Aldeyra Therapeutics by 22.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 62,429 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 11,506 shares during the last quarter. Gilder Gagnon Howe & Co. LLC acquired a new stake in Aldeyra Therapeutics in the 3rd quarter valued at approximately $3,010,000. Bank of New York Mellon Corp increased its holdings in Aldeyra Therapeutics by 139.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 49,842 shares of the biotechnology company’s stock valued at $396,000 after purchasing an additional 29,051 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new stake in Aldeyra Therapeutics in the 2nd quarter valued at approximately $237,000. 57.92% of the stock is currently owned by hedge funds and other institutional investors.
ALDX stock traded down $0.31 during trading on Tuesday, hitting $10.42. The stock had a trading volume of 116,904 shares, compared to its average volume of 273,876. The company has a current ratio of 8.11, a quick ratio of 8.11 and a debt-to-equity ratio of 0.03. Aldeyra Therapeutics has a twelve month low of $5.55 and a twelve month high of $16.70. The stock has a market cap of $230.72 million, a price-to-earnings ratio of -7.44 and a beta of 0.86.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Recommended Story: Initial Public Offering (IPO)
Get a free copy of the Zacks research report on Aldeyra Therapeutics (ALDX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.